Scholarlink

<p>The main objective of this study was to investigate the optimal post-left atrial appendage closure (LAAC) anticoagulation strategy, focusing on minimizing device-related thrombosis (DRT) and thromboembolism (TE) events without increasing bleeding risk. After successful LAAC, consecutive participants were treated with 45-day anticoagulants (rivaroxaban 15&#xa0;mg daily, dabigatran 110&#xa0;mg twice a day, and warfarin). The efficacy endpoints included DRT, TE, and hospital readmissions due to cardiac caused, while safety endpoints encompassed bleeding events, monitored over a 12-month follow-up period. The incidence of DRT was relatively lower in the rivaroxaban group compared to both the dabigatran and warfarin groups (rivaroxaban vs. dabigatran: HR = 0.504, 95% CI 0.208–1.223, log-rank <i>P</i> = 0.101; rivaroxaban vs. warfarin: HR = 0.468, 95% CI 0.167–1.316, log-rank <i>P</i> = 0.093). The median [interquartile range] length and width of DRT in the rivaroxaban group were 1.92 [1.68–2.15] mm and 1.49 [1.28–1.76] mm, both significantly lower than those in the dabigatran (length = 2.15 [1.99–2.25] mm, <i>P</i> = 0.036; width = 1.60 [1.54–1.85] mm, <i>P</i> = 0.035) and warfarin groups (length = 2.26 [2.11–2.44] mm, <i>P</i> = 0.006; width = 1.74 [1.54–1.85] mm, <i>P</i> = 0.006). Kaplan-Meier survival analysis indicated that procedural bleeding was more common in the warfarin group. The 12-month incidence of TE was significantly lower in the rivaroxaban group compared to the dabigatran (HR = 0.466, 95% CI 0.221–0.984, log-rank <i>P</i> = 0.029) and warfarin groups (HR = 0.456, 95% CI 0.188–0.966, log-rank <i>P</i> = 0.042). Long-term antithrombotic therapy with reduced dose of rivaroxaban significantly reduced the risk of DRT and composite endpoints without increasing bleeding events, compared to warfarin and dabigatran, for patients following LAAC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical effectiveness and safety comparison between direct oral anticoagulants and warfarin for nonvalvular atrial fibrillation patients following percutaneous left atrial appendage closure operation intervention: a prospective observational study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月2日

查看全文
  • Yao Yao,
  • Qinchun Jin,
  • Xiaochun Zhang,
  • Qianzhou Lv

摘要

The main objective of this study was to investigate the optimal post-left atrial appendage closure (LAAC) anticoagulation strategy, focusing on minimizing device-related thrombosis (DRT) and thromboembolism (TE) events without increasing bleeding risk. After successful LAAC, consecutive participants were treated with 45-day anticoagulants (rivaroxaban 15 mg daily, dabigatran 110 mg twice a day, and warfarin). The efficacy endpoints included DRT, TE, and hospital readmissions due to cardiac caused, while safety endpoints encompassed bleeding events, monitored over a 12-month follow-up period. The incidence of DRT was relatively lower in the rivaroxaban group compared to both the dabigatran and warfarin groups (rivaroxaban vs. dabigatran: HR = 0.504, 95% CI 0.208–1.223, log-rank P = 0.101; rivaroxaban vs. warfarin: HR = 0.468, 95% CI 0.167–1.316, log-rank P = 0.093). The median [interquartile range] length and width of DRT in the rivaroxaban group were 1.92 [1.68–2.15] mm and 1.49 [1.28–1.76] mm, both significantly lower than those in the dabigatran (length = 2.15 [1.99–2.25] mm, P = 0.036; width = 1.60 [1.54–1.85] mm, P = 0.035) and warfarin groups (length = 2.26 [2.11–2.44] mm, P = 0.006; width = 1.74 [1.54–1.85] mm, P = 0.006). Kaplan-Meier survival analysis indicated that procedural bleeding was more common in the warfarin group. The 12-month incidence of TE was significantly lower in the rivaroxaban group compared to the dabigatran (HR = 0.466, 95% CI 0.221–0.984, log-rank P = 0.029) and warfarin groups (HR = 0.456, 95% CI 0.188–0.966, log-rank P = 0.042). Long-term antithrombotic therapy with reduced dose of rivaroxaban significantly reduced the risk of DRT and composite endpoints without increasing bleeding events, compared to warfarin and dabigatran, for patients following LAAC.